Peptides Research Hub

Citation index

Søren Madsbad, MD, DMSc

University of Copenhagen, Hvidovre Hospital

Endocrinologist whose published research focuses on the clinical pharmacology of GLP-1 receptor agonists and other incretin-based therapies in type 2 diabetes.

Public profiles

Cited on Peptides Research Hub

  • Tirzepatide: research, pharmacology, and clinical evidence

    Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist approved for T2DM (Mounjaro) and chronic weight management (Zepbound). This pillar covers mechanism, half-life, bioavailability, pivotal trials, safety, and regulatory status.

  • Tirzepatide mechanism of action: dual GIP and GLP-1 receptor agonism

    Tirzepatide

    Tirzepatide activates both the GIP and GLP-1 receptors via a single 39-residue peptide with biased GLP-1 signaling and full GIP agonism. This article reviews structural design, receptor coupling, and downstream metabolic effects.

  • Tirzepatide Half-Life and Pharmacokinetics

    Tirzepatide

    Tirzepatide's mean terminal half-life is approximately 116.7 hours (≈ 5 days). This article covers absorption, distribution, the C20 fatty diacid albumin-binding strategy, and Aib2/Aib13 protection against DPP-4 cleavage.

  • Tirzepatide Safety Profile and Adverse Events in the Literature

    Tirzepatide

    This article summarizes adverse events from the SURPASS and SURMOUNT trial programs, the FDA boxed warning for thyroid C-cell tumors, and known cautions in pancreatitis, gallbladder disease, gastroparesis, and pregnancy.

  • Semaglutide: research, pharmacology, and clinical evidence

    Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). The SELECT trial demonstrated cardiovascular risk reduction in people with obesity but without diabetes. This pillar covers mechanism, half-life, pharmacokinetics, pivotal trials, safety, and regulatory status.

  • Semaglutide Mechanism of Action: GLP-1 Receptor Agonism

    Semaglutide

    Semaglutide selectively activates the GLP-1 receptor to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. This article explains the receptor pharmacology, downstream signaling, and the structural features that confer DPP-4 resistance and albumin binding.

  • Semaglutide Half-Life and Pharmacokinetics

    Semaglutide

    Semaglutide's mean terminal half-life is approximately 165 hours. This article covers the Aib8 substitution, C18 fatty diacid albumin-binding strategy, oral bioavailability with the SNAC enhancer, dose titration for Ozempic and Wegovy, and special-population pharmacokinetics.

  • Semaglutide Safety Profile and Adverse Events

    Semaglutide

    This article summarizes adverse events from semaglutide's pivotal programs, the boxed warning for thyroid C-cell tumors, gastrointestinal event frequencies, pancreatitis, gallbladder disease, the retinopathy worsening signal from SUSTAIN-6, post-marketing suicidal ideation review, and considerations in pregnancy and lactation.

  • Liraglutide: research, pharmacology, and clinical evidence

    Liraglutide is a once-daily GLP-1 receptor agonist marketed as Victoza (diabetes) and Saxenda (weight management). This pillar covers structure, mechanism, half-life, the LEADER cardiovascular outcomes trial, the SCALE weight-management program, safety, and regulatory status across five major jurisdictions.